Proteolix

Proteolix was acquired for $276 million in cash, plus up to $575 million in earnouts depending on the success of Proteolix's drug over the years, according to filings.

Cashing Out Start-Ups Gets More Complicated Pui-Wing Tam 2011

A world-renowned expert in the study of protein degradation pathways and previously a Co-Founder of Proteolix, Dr. Deshaies is Professor and Executive Officer of Biology at the

unknown title 2011

Proteolix was acquired for $276 million in cash, plus up to $575 million in earnouts depending on the success of Proteolix's drug over the years, according to filings.

unknown title 2011

Most recently, he was president and chief executive of Proteolix, a biotech company acquired by Onyx Pharmaceuticals in 2009.

SFGate: Don Asmussen: Bad Reporter Chronicle News Services 2011

Most recently, he was president and chief executive of Proteolix, a biotech company acquired by Onyx Pharmaceuticals in 2009.

SFGate: Don Asmussen: Bad Reporter 2011

Most recently, he was president and chief executive of Proteolix, a biotech company acquired by Onyx Pharmaceuticals in 2009.

SFGate: Don Asmussen: Bad Reporter Chronicle News Services 2011

Deshaies and Cohen on the Cleave technology, he was Associate Director at Proteolix where he was instrumental in the development of oncology drug candidate carfilzomib and PR-957 now ONX 0914, currently in preclinical studies.

unknown title 2011

Most recently, he was president and chief executive of Proteolix, a biotech company acquired by Onyx Pharmaceuticals in 2009.

SFGate: Don Asmussen: Bad Reporter Chronicle News Services 2011

Onyx will acquire Proteolix and its blood cancer drug candidate in deal worth up to $851M

Gaea Times (by Simple Thoughts) Breaking News and incisive views 24/7 2010

Proteolix is working on carfilzomib, a cancer-fighting proteasome inhibitor that is in a

Boston Business News - Local Boston News | Boston Business Journal 2010